Exogenous IL-10 and IL-4 down-regulate IL-6 production by SLE-derived PBMC

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Elevated interleukin-6 (IL-6) and interleukin-10 (IL-10) are implicated in systemic lupus erythematosus (SLE) pathogenesis.
• Previous studies suggested SLE monocytes might be resistant to IL-10's inhibitory effects on IL-6 production.

Purpose of the Study:

• To investigate the regulatory mechanisms of IL-6 expression in peripheral blood mononuclear cells (PBMCs) from SLE patients compared to healthy controls.
• To determine if SLE PBMCs exhibit altered responses to regulatory cytokines like IL-10, IL-4, and TGF-beta 1.

Main Methods:

• Compared the effects of exogenous recombinant IL-10 (rIL-10) and IL-4 (rIL-4) on IL-6 production in SLE (N=51) and control (N=21) PBMCs.
• Analyzed IL-6 mRNA decay rates and the impact of cytokine neutralization (IL-1 beta, TNF-alpha) and exogenous cytokines on IL-6 transcription and stability.
• Measured the time kinetics and levels of IL-6, IL-10, and IL-1 beta.

Main Results:

• SLE PBMCs showed normal reduction of IL-6 production in response to exogenous rIL-10 and rIL-4, similar to controls.
• IL-6 mRNA decay was significantly delayed in active SLE patients (P < 0.001).
• IL-10 and IL-1 beta levels and kinetics were lower than IL-6 levels, suggesting potential imbalances in regulatory cytokine availability.

Conclusions:

• Contrary to prior suggestions, SLE PBMCs do not appear refractory to IL-10-mediated IL-6 inhibition.
• IL-6 overexpression in SLE may stem from delayed IL-6 mRNA decay and suboptimal kinetics/availability of regulatory cytokines like IL-10 and IL-1 beta.
• These findings highlight the importance of cytokine dynamics in SLE pathogenesis.